---
layout: archive
title: "Articles"
permalink: /publications/
author_profile: true
---
<br>
<p><strong>Peer-reviewed Statistical Articles:</strong>
<br>
<br>
<strong>Zhan, T.</strong><sup>†</sup>, Zhang, J., Shu, L. and Gu, Y. (2025). <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/sim.70196" target="_blank">An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing with Concurrent Controls in Platform Trials</a>. <em>Statistics in Medicine</em>, 44(15-17), e70196.
<br>
<br>
<strong>Zhan, T.</strong><sup>†</sup> and, Gu, Y. (2025). <a href="https://www.tandfonline.com/doi/abs/10.1080/10618600.2025.2507428" target="_blank">Semiparametric Weighted Spline Regression (SWSR) in Confirmatory Clinical Trials with Time-Varying Placebo Effects</a>. <em>Journal of Computational and Graphical Statistics</em>.

Zhan, T.† and Kang, J.† (2025). A general, flexible and harmonious framework to construct interpretable functions in regression analysis. Biometrics, (81)1.

Zhan, T.† (2024). A class of computational methods to reduce selection bias when designing Phase 3 clinical trials. Statistics in Medicine, 43(10), 1993-2006.

Zhan, T.†, Fu, H. and Kang, J. (2024). Deep Neural Networks Guided Ensemble Learning for Point Estimation. Statistics in Biopharmaceutical Research, 16(2), 270-278.

Zhan, T.† (2022). DL 101: Basic introduction to deep learning with its application in biomedical related fields. Statistics in Medicine, 41 (26), 5365-5378.

Li Y.†, Feng D., Sui Y., Li H., Song Y., Zhan T., Cicconetti G., Jin M., Wang H., Chan I. and Wang X. (2022). Analyzing longitudinal binary data in clinical studies. Contemporary Clinical Trials, 106717.

Zhan, T.† and Kang, J. (2022). Finite-Sample Two-Group Composite Hypothesis Testing via Machine Learning. Journal of Computational and Graphical Statistics, 31(3), 856-865.

Zhan, T.†, Hartford, A., Kang, J. and Offen, W. (2022). Optimizing Graphical Procedures for Multiplicity Control in a Confirmatory Clinical Trial via Deep Learning. Statistics in Biopharmaceutical Research, 14(1), 92-102.

Zhan, T.†, Zhou, Y., Geng, Z., Gu, Y., Kang, J., Wang, L., Huang X. and Slate, E. H. (2021). Deep Historical Borrowing Framework to Prospectively and Simultaneously Synthesize Control Information in Confirmatory Clinical Trials with Multiple Endpoints. Journal of Biopharmaceutical Statistics, 32 (1), 90-106.

Zhan, T.†, Cui, L., Geng, Z., Zhang, L., Gu, Y. and Chan, I. S. (2021). A Practical Response Adaptive Block Randomization (RABR) Design with Analytic Type I Error Protection. Statistics in Medicine, 40(23), 4947-4960.

Cui, L.†, Zhan, T., Zhang, L., Geng, Z., Gu, Y. and Chan, I.S. (2021). An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency. Statistical Methods in Medical Research, 30(4), 1013-1025.

Zhan, T. and Schaubel, D. E.† (2020). Semiparametric regression methods for temporal processes subject to multiple sources of censoring. Canadian Journal of Statistics, 48(2), 222-237.

Zhan, T.†, Zhang, H., Hartford, A. and Mukhopadhyay, S. (2020). Modified Goldilocks Design with strict type I error control in confirmatory clinical trials. Journal of Biopharmaceutical Statistics, 30(5), 821-833.

Zhan, T. and Schaubel, D. E.† (2019). Semiparametric temporal process regression of survival-out-of-hospital. Lifetime Data Analysis, 25(2), 322-340.

Jiang, H.† and Zhan, T. (2017). Unit-free and robust detection of differential expression from RNA-Seq data. Statistics in Biosciences, 9(1), 178-199.

Peer-reviewed Medical Articles
Ackerman, L.S., Schlosser, B.J., Zhan, T., Prajapati, V.H., Fretzin, S., Takahashi, H., Huang, X., Camp, H.S. and Kimball, A.B. (2025). Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. Journal of the American Academy of Dermatology.

Lebwohl, M.†, Bukhalo, M., Gold, L.S., Glick, B., Llamas-Velasco, M., Sanchez-Rivera, S., Pan, A., Zhan, T., Drogaris, L., Douglas, K. and John, G.S. (2024). A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. Journal of the American Academy of Dermatology, 91 (6), 1150-1157 .

Strober, B.†, Bachelez, H., Crowley, J., Elewski, B.E., Gooderham, M., Menter, A., Strohal, R., Chen, M.M., Wu, T., Zhan, T. and Photowala, H. (2024). Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology, 38(5), 864-872.

Kimball, A.B.†, Prens, E.P., Passeron, T., Maverakis, E., Turchin, I., Beeck, S., Drogaris, L., Geng, Z., Zhan, T., Messina, I. and Bechara, F.G. (2023). Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial. Dermatology and Therapy, 13(5), 1099-1111.

Gooderham, M.†, Pinter, A., Ferris, L.K., Warren, R.B., Zhan, T., Zeng, J., Soliman, A.M., Kaufmann, C., Kaplan, B., Photowala, H. and Strober, B. (2022). Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post-hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 36(6), 855-865.

Crowley, J.J.†, Langley, R.G., Gordon, K.B., Pinter, A., Ferris, L.K., Rubant, S., Photowala, H., Xue, Z., Wu, T., Zhan, T. and Beeck, S. (2022). Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy, 12(2), 561-575.

Blauvelt, A.†, Gordon, K.B., Lee, P., Bagel, J., Sofen, H., Lockshin, B., Soliman, A.M., Geng, Z., Zhan, T., Alperovich, G. and Stein Gold, L. (2021). Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 33 (4), 2085-2093.

Strober, B.†, Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T. and Foley, P. (2020). Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies. Journal of the European Academy of Dermatology and Venereology, 34(12), 2830-2838.

McDaniel, A. S., Alva, A., Zhan, T., Xiao, H., Cao, X., Gursky, A., Siddiqui, J., Chinnaiyan, A.M., Jiang, H., Lee, C.T. and Mehra, R.† (2016). Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma. European Urology Focus, 1(3), 265-268.

Magers, M. J., Zhan, T., Udager, A. M., Wei, J. T., Tomlins, S. A., Wu, A. J., Kunju, L.P., Lew, M., Feng, F.Y., Hamstra, D.A., Siddiqui, J., Chinnaiyan, A.M., Montgomery J.S., Weizer, A.Z., Morgan, T.M., Hollenbeck, B.K., Miller, D.C., Palapattu, G.S., Jiang, H. and Mehra, R.† (2015). Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Medical Oncology, 32(11), 249.

Book Chapters
Zhan, T.† (2023). Deep Learning Constructed Statistics with Application to Adaptive Designs for Clinical Trials. Case Studies in Innovative Clinical Trials, Chapman and Hall/CRC.

Zhan, T.†, Fang, Y. and He, W. (2023). Privacy-Preserving Record Linkage for Real-World Data. Real-World Evidence in Medical Product Development, Springer.

Dissertation
Zhan, T. (2017). Semiparametric Functional Temporal Process Regression of Prevalence Outcomes. Ph.D. Thesis. University of Michigan.

Zhan, T. (2013). Genetics of Runt-dependent regulation in Drosophila embryo. B.S. Thesis. Stony Brook University.




